vTv Therapeutics to Participate in Upcoming May Investor Conferences
vTv Therapeutics (Nasdaq: VTVT) said management will attend two investor conferences in May 2026: H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
vTv Therapeutics (Nasdaq: VTVT) said management will attend two investor conferences in May 2026: H.C. Wainwright BioConnect in New York on May 19, 2026 and Alliance Global Partners Healthcare Company Showcase (virtual) on May 20, 2026.
Live fireside chat webcasts and replays will be available on the company website's Media & Events section.
Details
News Market Reaction – VTVT
On May 7, the day this news came out, VTVT closed 2.02% below the previous close.
Data tracked by StockTitan Argus for the May 7 session.
Key Figures
- H.C. Wainwright conference date
- May 19, 2026
- H.C. Wainwright 4th Annual BioConnect Investor Conference
- H.C. Wainwright time
- 12:30 PM ET
- Fireside chat schedule
- Alliance Global Partners date
- May 20, 2026
- Alliance Global Partners Healthcare Company Showcase
- Alliance Global Partners time
- 4:20 PM ET
- Fireside chat schedule
Historical Context
-
Granted 4,000 stock options to a non-executive employee under inducement plan.
-
Announced fireside chat and 1x1 meetings at 38th Annual ROTH Conference.
-
Reported 2025 results, cash of $88.9M, and CATT1 Phase 3 enrollment timing.
-
Outlined participation in Oppenheimer and TD Cowen healthcare conferences.
-
Expanded Newsoara license for HPP737 with $20M upfront and milestone structure.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
type 1 diabetes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May:
H.C. Wainwright 4th Annual BioConnect Investor Conference
Format: Fireside Chat & one-on-one investor meetings
Date: Tuesday, May 19, 2026
Time: 12:30 PM ET
Location: New York, NY
Webcast Link
Alliance Global Partners Healthcare Company Showcase
Format: Fireside Chat
Date: Wednesday, May 20, 2026
Time: 4:20 PM ET
Location: Virtual Event
Event Webcast Link
Live webcasts of the fireside chats will be available on the Media & Events section of the Company’s website at vtvtherapeutics.com. Replays of the webcasts will be available following the event.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a U.S. Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased glucokinase activity independently of insulin. These findings support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.